Skip to main
PYPD
PYPD logo

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid Ltd has demonstrated a significant positive outlook with its proprietary PLEX technology, which enables targeted drug delivery and has shown promising results in the Phase 3 SHIELDI clinical study for its flagship product, D-PLEX100, aimed at preventing surgical site infections. The company experienced lower-than-expected net loss per share, attributed to an increase in share count due to warrant exercises, suggesting strong investor confidence and participation. Additionally, the impending pre-NDA meeting, expected to yield positive outcomes, coupled with the strategic collaboration with AdvanzPharma in the EU, underscores PolyPid's potential for successful product approval and market entry.

Bears say

PolyPid Ltd faces a negative outlook primarily due to the potential for its clinical agents to fail in delivering statistically significant results, which would significantly diminish the value of its product candidates. Additionally, even if the products demonstrate clinical success, there exists a risk of non-approval by regulatory agencies, further jeopardizing the company's value. Compounding these challenges, the complicated patent procedures raise concerns about potential revenue erosion beginning in 2036, contributing to the overall pessimistic financial outlook for the company.

PolyPid (PYPD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PolyPid (PYPD) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.